BEIJING, March 10 (Xinhua) -- In a bid to strengthen drug registration, China's drug watchdog is revising the existing drug registration and management provisions and will put the new one into effect this year.
State Food and Drug Administration released the revised version Saturday to solicit public opinions on drug registration and management.
"The new draft is focused on closing registration loopholes in existing provisions and encouraging researches of new drugs," said Wu Zhen, deputy director of the Administration.
Consisting of 15 chapters, or 211 articles, the new provisions is drafted according to China's Drug Management Law and based on extensive researches and expert opinions.
Several drug safety incidents occurred in China last year, the most notorious one causing the deaths of at least six patients and severe side-effects in more than 80 others.